2011-09-09Zeitschriftenartikel DOI: 10.1371/journal.pone.0023946
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort.
Lunzen, Jan van
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by modelling different treatment scenarios. Methods: Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the Centre of Disease Control- (CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder including German taxes. Results: During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for antiretroviral drugs of J812,877,356 were determined according to an average of J42.08 per day (J7.52 to J 217.70). Since cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptaseinhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively). Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%. Conclusions: Analysis of the data of this nationwide study reflects disease-specific health services research and will give insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the German health care system.
Dateien zu dieser Publikation
Anzeige der Publikationen mit ähnlichem Titel, Autor, Urheber und Thema.
2012-12-28ZeitschriftenartikelEpidemiology and cost of herpes zoster and postherpetic neuralgia in Germany Ultsch, Bernhard; Köster, Ingrid; Reinhold, Thomas; Siedler, Anette; Krause, Gérard; Icks, Andrea; Schubert, Ingrid; Wichmann, OleAfter acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)—a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic ...
2010-10-14ZeitschriftenartikelMethicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe Köck, Robin; Becker, Karsten; Cookson, B.; Gemert-Pijnen, J. E. van; Harbarth, S.; Kluytmans, J.; Mielke, Martin; Peters, G.; Skov, R. L.; Struelens, M. J.; Tacconelli, E.; Torné, A. Navarro; Witte, Wolfgang; Friedrich, Alexander W.Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare- and community-associated infections worldwide. Within the healthcare setting alone, MRSA infections are estimated to affect more than 150,000 ...
2011-12-27ZeitschriftenartikelEvaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: a retrospective model analysis. Müller, I.; Freitag, M. H.; Poggensee, Gabriele; Scharnetzky, E.; Straube, E.; Schoerner, Ch.; Hlobil, H.; Hagedorn, Hans-Jochen; Stanek, G.; Schubert-Unkmeir, A.; Norris, D. E.; Gensichen, J.; Hunfeld, K.-P.Background: Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials ...